Closed Viral Vector Manufacturing Platforms Market Report 2026

The closed viral vector manufacturing platforms market size has grown rapidly in recent years. It will grow from $1.96 billion in 2025 to $2.22 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to rising gene therapy clinical trials, increased use of viral vectors in vaccine development, expansion of cell and gene therapy research programs, growing regulatory focus on sterile manufacturing, early adoption of closed processing technologies.

The closed viral vector manufacturing platforms market size is expected to see rapid growth in the next few years. It will grow to $3.63 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing commercialization of gene therapies, rising demand for large-scale viral vector supply, growing investments in advanced biomanufacturing infrastructure, expansion of contract manufacturing capacity, increasing focus on process standardization and automation. Major trends in the forecast period include increasing adoption of fully closed and automated production systems, rising demand for scalable viral vector manufacturing platforms, growing integration of single-use and modular components, expansion of end-to-end closed processing workflows, enhanced focus on regulatory compliance and contamination control.

The increasing number of clinical trials is expected to drive the growth of the closed viral vector manufacturing platforms market in the coming years. Clinical trials are carefully designed studies conducted in humans to evaluate the safety, efficacy, and proper use of new medical therapies or interventions. The demand for clinical trials is rising due to the growing need for innovative treatments, as the increasing prevalence of chronic and complex diseases fuels the development and testing of new drugs and therapies to address unmet medical needs. Closed viral vector manufacturing platforms facilitate clinical trials by providing consistent, sterile production of viral vectors, ensuring the safety and reliability of the therapies being studied. For example, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, the total number of industry-sponsored clinical trials launched in the UK increased from 411 in 2022 to 426 in 2023. As a result, the rising number of clinical trials is contributing to the growth of the closed viral vector manufacturing platforms market.

Major companies operating in the closed viral vector manufacturing platforms market are focusing on developing advanced solutions, such as nitro controllers, to manage nitrogen-induced stress or toxicity in cell cultures. Nitro controllers are devices or systems designed to monitor and regulate nitrogen levels or reactive nitrogen species in bioprocesses, ensuring optimal conditions for cell growth and product formation. For example, in May 2025, Univercells Technologies, a Belgium-based biotechnology company, introduced the scale-X nitro controller. It is a compact and cost-effective system designed for large-scale viral vector and vaccine production. The system is compatible with 200 m² and 600 m² scale-X nitro bioreactors and supports both adherent and suspension cell cultures. It enables efficient production of AAV, lentiviral vectors, exosomes, and oncolytic viruses. Furthermore, it facilitates rapid scale-up, allowing the transition from research and development to commercial manufacturing within eight months.

In November 2023, Ajinomoto Co. Inc., a Japan-based biotechnology company, acquired Forge Biologics for $545 million. Through this acquisition, Ajinomoto gained Forge’s 200,000-square-foot cGMP facility, the Hearth, in Columbus, Ohio, along with a workforce of over 300 employees. This expansion enhances Ajinomoto’s global gene therapy manufacturing capabilities, strengthening its contract development and manufacturing services for AAV and plasmid-based therapies. Forge Biologics is a US-based company focused on closed viral vector manufacturing platforms.

Major companies operating in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, Genesail Biotech Co. Ltd.

North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the closed viral vector manufacturing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the closed viral vector manufacturing platforms market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the closed viral vector manufacturing platforms market by increasing the cost of imported bioreactors, filtration systems, automation hardware, sensors, and precision control components used across upstream, downstream, and fill-finish workflows. Pharmaceutical and biotechnology manufacturers in North America and Europe are most affected due to reliance on specialized imported equipment, while Asia-Pacific faces cost pressure on platform assembly and export-oriented manufacturing. These tariffs are increasing capital expenditure requirements and extending facility deployment timelines. However, they are also encouraging localized equipment manufacturing, regional supplier development, and long-term investments in domestic closed-system biomanufacturing capabilities.

The closed viral vector manufacturing platforms market research report is one of a series of new reports that provides closed viral vector manufacturing platforms market statistics, including closed viral vector manufacturing platforms industry global market size, regional shares, competitors with a closed viral vector manufacturing platforms market share, detailed closed viral vector manufacturing platforms market segments, market trends and opportunities, and any further data you may need to thrive in the closed viral vector manufacturing platforms industry. This closed viral vector manufacturing platforms market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Closed viral vector manufacturing platforms are fully enclosed systems built to produce viral vectors under strictly controlled and sterile conditions. They combine multiple production steps, such as cell growth, vector assembly, purification, and formulation, within a sealed environment to reduce contamination and limit human intervention. These platforms enhance process consistency, scalability, and regulatory compliance, ensuring high-quality vector production while maintaining safety and efficiency across the production cycle.

The main product types of closed viral vector manufacturing platforms include plasmid deoxyribonucleic acid (DNA), lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, and others. Plasmid DNA comprises circular, double-stranded DNA molecules that act as essential templates for generating viral vectors or as direct gene delivery tools in non-viral gene therapy. Different workflows include upstream processing, downstream processing, and fill-finish, and are applied for gene therapy, vaccines, cell therapy, and others. These platforms are utilized by several end users, including pharmaceutical and biotechnology companies, academic and research institutes, contract manufacturing organizations, and others.

The closed viral vector manufacturing platforms market includes revenues earned by entities by providing services such as upstream process development, downstream process development, analytical development, and formulation development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.